No results for ‘’
ERIS Lifesciences Ltd
₹1458.20
(9.13%)
Mon, 25 May 2026, 02:00 pm
Health Technology
Pharmaceuticals: Major
24.5KERIS Lifesciences PE Ratio
| Particulars | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 37.15 | 30.48 | 17.06 | 23.13 | 23.06 | 20.38 | 29.22 | 54.87 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0 | 12.69 | 7.70 | 3.86 | 5.21 | 4.91 | 3.54 | 4.42 | 6.76 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0 | 12.88 | 9.02 | 4.71 | 6.78 | 6.95 | 4.62 | 5.70 | 6.67 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 48.42 | 43.84 | 18.70 | 21.91 | 24.68 | 28.60 | 27.55 | 20.89 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 0 | 112.24B | 87.36B | 49.3B | 80.9B | 92.36B | 86.02B | 134.71B | 219.77B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 34.75 | 25.15 | 13.05 | 18.42 | 18.62 | 15.74 | 19.22 | 21.35 |
| Debt to equity ratio | 0.10 | 0.02 | 0 | 0 | 0 | 0 | 0.44 | 0.15 | 0.01 | 0 | 0.04 | 0.40 | 1.08 | 0.87 |
| Return on equity % | 0 | 75.59 | 50.04 | 40.29 | 47.26 | 56.97 | 41.98 | 28.91 | 24.23 | 24.72 | 23.31 | 18.62 | 16.40 | 12.93 |
ERIS Lifesciences Ltd Price to Earnings Ratio
The ERIS Lifesciences Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate ERIS Lifesciences Ltd's valuation, profitability, and overall financial performance. Tracking the ERIS Lifesciences Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
ERIS Lifesciences Ltd (NSE: ERIS, BSE: 540596) is currently trading at ₹1458.20, with a market capitalization of ₹185.28B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the ERIS Lifesciences Ltd Price to Earnings Ratio is essential for fundamental analysis.
ERIS Lifesciences Ltd Price to Earnings Ratio Current Value
The current ERIS Lifesciences Ltd Price to Earnings Ratio stands at 54.87.
The latest ERIS Lifesciences Ltd Price to Earnings Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
ERIS Lifesciences Ltd Price to Earnings Ratio Historical Trend
The ERIS Lifesciences Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 54.87
- 2023: 29.22
- 2022: 20.38
- 2021: 23.06
- 2020: 23.13
The recent rise in ERIS Lifesciences Ltd Price to Earnings Ratio suggests strengthening valuation trends and improving market sentiment.
What ERIS Lifesciences Ltd Price to Earnings Ratio Indicates for Investors
The ERIS Lifesciences Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
ERIS Lifesciences Ltd Price to Earnings Ratio Analysis Summary
The ERIS Lifesciences Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking ERIS Lifesciences Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of ERIS Lifesciences Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.